stockrow
Saturday 7 November 2026
Export NMRA’s income statement to Excel — free account
Neumora Therapeutics, Inc.
NMRA Healthcare Biotechnology
- EPS
- +30.3%
- Free cash flow
- +24.5%
- Total debt
- +172.0%
Quarter to June 2026, against a year earlier
0.49
0.00
0.00%
Follow NMRA
Alert me
Neumora Therapeutics, Inc. (NMRA) P/E ratio
Neumora Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BDTX Black Diamond Therapeutics, Inc. compare | n/m |
| CBUS Cibus, Inc. compare | n/m |
| LENZ LENZ Therapeutics, Inc. compare | n/m |
| VANI Vivani Medical, Inc. compare | n/m |
| NMRA Neumora Therapeutics, Inc. | n/m |
| SEER Seer, Inc. compare | n/m |
| VXRT VAXART, INC. compare | 2.8× |
| ICCC ImmuCell Corporation compare | 117× |
| RTSN Retension Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)